Apixiban Efficacy

Apixiban (Bristol Myers Squibb, Pfizer) efficacy and safety data from the AVERROES study were reported at the European Society of Cardiology meeting August 31, 2010 in Stockholm. Subjects in the study had a significantly lower risk of stroke and systemic embolic events without increase risk of bleeding. Apixiban is one of the new oral anti-Xa drugs that may one day replace warfarin. Click AVERROES data for a full description.